rs1800497 — ANKK1/DRD2 Taq1A (Glu713Lys)
Risk factor · ~20% global (A1 allele)
rs1800497 (Taq1A) is near the DRD2 dopamine receptor gene and reduces D2 receptor density in the striatum by 30-40%. It is associated with increased risk of substance use disorders, reward-seeking behavior, and obesity.
Molecular Mechanism
The variant is in the ANKK1 gene, ~10 kb downstream of DRD2, but affects DRD2 expression through regulatory mechanisms. Reduced D2 receptor availability creates a 'reward deficiency syndrome' where individuals seek more intense stimulation to achieve normal dopamine signaling.
Peptide Therapeutic Relevance
DRD2-modulating peptides and dopamine system-targeting neuropeptides are emerging therapeutic approaches for addiction. PepFold generates candidates exploring D2 receptor positive allosteric modulation.
Condition: Addiction Susceptibility (DRD2/OPRM1)
Genetic variation in dopamine (DRD2/ANKK1) and opioid (OPRM1) receptor systems creates differential vulnerability to substance use disorders. Personalized pharmacotherapy guided by genotype is an emerging paradigm.
Prevalence: ~35 million people worldwide with substance use disorders (UNODC 2023)
Analyze rs1800497 with PepFold
Submit rs1800497 and get ranked peptide candidates with 3D structures and synthesis protocols in under 2 minutes.